Urgent Intervention: Doctor-MPs Flag "Humanitarian Emergency" in Rare Disease Treatment to Prime Minister

Spread the Message

Read Time:4 Minute, 42 Second

New Delhi — In a significant intervention bridging policy and medical ethics, the Indian Medical Parliamentarians’ Forum (IMPF) has formally approached Prime Minister Narendra Modi and Union Health Minister J.P. Nadda, raising an urgent alarm over a “treatment crisis” facing patients with rare diseases in India. The forum, comprised of 45 Members of Parliament who are also medical professionals, described the current situation as a mounting humanitarian emergency, citing the deaths of over 60 children and young adults due to treatment delays and funding interruptions.

The representation, led by IMPF Chairperson and Rajya Sabha MP Dr. Anil Bonde, highlights critical gaps in the implementation of the National Policy for Rare Diseases (NPRD) 2021. The MPs contend that while the policy was a landmark step, its current financial structures are failing patients requiring lifelong therapy, specifically those battling Lysosomal Storage Disorders (LSDs).

The Crisis: Beyond the ₹50 Lakh Cap

At the heart of the crisis is the financial cap mandated by the NPRD 2021. The policy currently provides a one-time financial assistance of up to ₹50 lakh for patients suffering from rare diseases, amenable to treatment at designated Centers of Excellence (CoEs). While this amount is substantial for curative, one-time procedures (like bone marrow transplants), it is proving insufficient for conditions requiring chronic, lifelong management.

“The situation has escalated into a humanitarian emergency,” the IMPF statement noted. Data presented by the forum reveals that approximately 60 patients have already exhausted the ₹50 lakh limit, leaving them with no viable financial path to continue their life-saving Enzyme Replacement Therapy (ERT). Furthermore, nearly 100 individuals currently receiving therapy are at imminent risk of being forced off treatment as their allocated funds near depletion.

Medical experts emphasize that for conditions like Gaucher disease, Pompe disease, and Fabry disease—collectively known as Lysosomal Storage Disorders—treatment is not “one and done.” These patients require regular infusions of the missing enzyme to survive.

Medical Implications of Interrupted Care

LSDs are ultra-rare genetic metabolic disorders caused by enzyme deficiencies, leading to a toxic buildup of materials in the body’s cells. Without Enzyme Replacement Therapy (ERT), this buildup causes irreversible organ damage.

“Even brief breaks in ERT can trigger acute metabolic crises, organ failure, and often death,” explained a senior geneticist familiar with the challenges at public hospitals. “When funding stops, the disease doesn’t just pause; it rebounds aggressively. We are seeing children regress physically and neurologically within weeks of stopping medication.”

The IMPF’s letter underscored this grim reality, noting that treatment interruptions are turning administrative bottlenecks into life-and-death barriers.

Policy Gaps and Legal Interventions

The intervention by the medical parliamentarians comes against a backdrop of increasing judicial scrutiny. In October 2024, the Delhi High Court directed the Ministry of Health and Family Welfare to immediately release funds for patients who had exhausted the ₹50 lakh cap, mandating the establishment of a National Fund for Rare Diseases. However, implementation on the ground remains sluggish.

Advocacy groups have long argued that the current framework lacks a “continuum of care” model.

“The ₹50 lakh assistance is a bridge to nowhere for chronic patients,” says Prasanna Shirol, Co-founder of the Organization for Rare Diseases India (ORDI). “Families are facing catastrophic financial burdens. Once the government aid is exhausted, there is no alternative funding mechanism to sustain these expensive therapies, which can cost anywhere from ₹10 lakh to over ₹1 crore annually depending on the patient’s weight.”

Key Demands for Structural Change

The IMPF has outlined three specific demands to the Prime Minister to avert further fatalities:

Immediate Waiver of the Cap: An urgent extension or waiver of the ₹50 lakh limit for patients with chronic rare diseases to prevent therapy discontinuation.
Continuum-of-Care Framework: The creation of a sustainable, long-term funding model under the NPRD to ensure uninterrupted treatment, moving beyond the “one-time grant” approach.
Streamlined Governance: Urgent reforms in the utilization of NPRD funds to remove bureaucratic delays at Centers of Excellence (CoEs), ensuring that allocated money reaches patients faster.

Public Health Implications

While rare diseases are individually uncommon, collectively they represent a significant public health challenge. Estimates suggest that LSDs affect 1 in 7,000–8,000 births. With India’s population, this translates to an estimated 1-10 lakh individuals living with these conditions, though the lack of a national registry makes precise numbers difficult to ascertain.

The move by the IMPF is significant because it represents a bipartisan, professional consensus within Parliament. By leveraging their medical expertise, these MPs are validating the long-standing claims of patient advocacy groups: that without a recurring funding model, the NPRD 2021 cannot fulfill its promise of “Health for All.”

Conclusion

The appeal to the Prime Minister represents a critical juncture for India’s rare disease community. With over 60 lives already lost to delays and hundreds more hanging in the balance, the medical parliamentarians have made it clear that the time for policy review is over—and the time for emergency intervention is now. As the government reviews the representation, thousands of families wait in hope that their “rare” condition will finally receive the mainstream attention it requires.

Medical Disclaimer:

This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.